TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC

被引：0

作者：

Forster, M. ^{[1
]}

Krebs, M. ^{[2
,3
]}

Majem, M. ^{[4
]}

Peguero, J.

Clay, T. ^{[5
]}

Felip, E. ^{[6
]}

Iams, W. ^{[7
]}

Roxburgh, P. ^{[8
,9
]}

Doger, B. ^{[10
]}

Bajaj, P. ^{[11
]}

Kefas, J. ^{[12
]}

Scott, J. A. ^{[13
]}

Joaquin, A. Barba ^{[4
]}

Mueller, C. ^{[14
]}

Triebel, F. ^{[15
]}

机构：

[1] Univ Coll London Hosp NHS Fdn, Canc Inst, UCL, London, England

[2] Univ Manchester, Div Canc Sci, Manchester, England

[3] Christie NHS Fdn Trust, Manchester, England

[4] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[5] Hosp St John God Subiaco, Perth, Australia

[6] Vall Hebron Univ Hosp, Barcelona, Spain

[7] Vanderbilt Ingram Canc Ctr, Div Hematol Oncol, Nashville, TN USA

[8] Univ Glasgow, Inst Canc Sci, Wolfson Wohl Canc Res Ctr, Glasgow, Scotland

[9] Beatson West Scotland Canc Ctr, Glasgow, Scotland

[10] Fdn Jimenez Diaz, Madrid, Spain

[11] Tasman Oncol, Southport, Australia

[12] Univ Coll London Hosp NHS Trust, London, England

[13] Christie NHS Fdn Trust, Manchester, England

[14] Immutep GmbH, Berlin, Germany

[15] Immutep SAS, Orsay, France

来源：

关键词：

LAG-3; NSCLC; PD-1/PD-L1; refractory;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP08.01-10

引用

页码：S395 / S395

页数：1